Suspected de novo heart failure in outpatient care: the REVOLUTION HF study

• Published in: European heart journal Vol. 46; no. 16; pp. 1493 - 1503
• Main Authors: Anderson, Lisa, Bayes-Genis, Antoni, Bodegård, Johan, Mullin, Katrina, Gustafsson, Stefan, Rosano, Giuseppe M C, Sundström, Johan
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 22.04.2025
• Subjects: Aged; Aged, 80 and over; Ambulatory Care; Biomarkers - blood; Clinical Research; De novo heart failure; Dyspnoea; Echocardiography; Female; Health Care Costs - statistics & numerical data; Heart Failure - blood; Heart Failure - diagnosis; Heart Failure - economics; Heart Failure - epidemiology; Heart Failure - mortality; Heart Failure - therapy; Hospitalization - economics; Hospitalization - statistics & numerical data; Humans; Male; Middle Aged; Natriuretic Peptide, Brain - blood; NT-proBNP testing; Peptide Fragments - blood; Peripheral oedema; SGLT2i; Sweden - epidemiology; Sweden; Dyspnoea; Echocardiography; NT-proBNP testing; SGLT2i; De novo heart failure; Peripheral oedema
• ISSN: 0195-668X; 1522-9645; 1522-9645
• DOI: 10.1093/eurheartj/ehaf034

Ambulatory patients presenting with signs or symptoms of heart failure (HF) should undergo natriuretic peptide testing. Rates of death, HF hospitalization, and healthcare costs were examined in patients thus identified with suspected de novo HF. This population-based study (REVOLUTION HF) encompassing two large healthcare regions in Sweden examined patients who presented to outpatient care for the first time between 1 January 2015 and 31 December 2020, who had a recorded sign (peripheral oedema) or symptom (dyspnoea) of HF, and whose N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured >300 ng/L within ±30 days of that sign or symptom. Characteristics, outcomes, healthcare patterns, and healthcare costs for these patients were followed for 1 year. Comparisons were made with matched controls without history of HF, its signs, its symptoms, or elevated NT-proBNP. Overall, 5942 patients (median age 78.7 years; 54% women) presented with suspected de novo HF. Within 1 year, 29% had received a HF diagnosis. Patients with suspected de novo HF had higher rates of all-cause death (11.7 vs. 6.5 events/100 person-years) and HF hospitalizations (12.5 vs. 2.2 events/100 person-years) than matched controls (n = 2048), with the highest event rates in the weeks after presentation. Rates were higher with higher NT-proBNP levels. Although some patients already used HF guideline-directed medical therapies for other indications, initiation of new medications was variable. Healthcare costs were higher in patients with suspected de novo HF than in matched controls, driven mostly by HF and chronic kidney disease. Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.